Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA tickerDefense World · Oct 11, 2026
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary DiseaseGlobeNewsWire · Oct 9, 2026
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity PlansDefense World · Oct 7, 2026
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha · Oct 6, 2026
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome TranscriptSeeking Alpha · Sep 28, 2026
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026GlobeNewsWire · Sep 17, 2026Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$28.02 | -$12.31 | Beat |
| May 12, 2026 | -$26.00 | $75.60 | Beat |
| Apr 6, 2026 | -$3.59 | -$3.50 | Beat |
| Nov 12, 2025 | -$40.00 | -$50.00 | Miss |
| Aug 11, 2025 | -$56.00 | -$68.00 | Miss |
| May 13, 2025 | -$48.00 | -$68.00 | Miss |